PSNL
Personalis, Inc.
Diagnostics & Research · Healthcare · United States
15.82
close · 2026-10-30
value
5
cheaper than peers5
quality
37
stronger fundamentals37
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| price to book | 7.16× | 40 |
| cash flow yield, 3 years ago | -7.1% | 24 |
| cash flow yield, 2 years ago | -4.0% | 24 |
| earnings yield, 2 years ago | -14.2% | 24 |
| earnings yield, 3 years ago | -15.7% | 22 |
| cash flow yield, 1 year ago | -2.8% | 21 |
| earnings yield, latest year | -5.8% | 21 |
| earnings yield, 1 year ago | -8.7% | 18 |
| cash flow yield, latest year | -4.7% | 18 |
| price to sales | 24.25× | 5 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 30.0% | 85 |
| debt to equity | 16.2% | 81 |
| return on equity | -50.3% | 9 |
| operating margin | -150.2% | 2 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$56.0M |
| employees | 259 |
| first trade | 2019-06-20 |
| next earnings | 2026-08-04 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -0.91 | -1.37 | -2.25 | -2.48 | not reported |
| free cash flow | -$79.5M | -$46.8M | -$67.2M | -$120.1M | not reported |
| net income | -$81.3M | -$81.3M | -$108.3M | -$113.3M | not reported |
| revenue | $69.6M | $84.6M | $73.5M | $65.0M | not reported |
| unusual items | not reported | $0 | -$13.6M | $0 | $0 |